Efonidipine exhibits high affinity for T-type calcium channels, blocking them via a combination of tonic and use-dependent mechanisms.
Answers are grounded in this paper and cite their sources.
Efonidipine's dual T/L-type potency in animal channels may guide preclinical blocker design; leaves open human translation and clinical testing.
We compared detailed efficacy of efonidipine and nifedipine, dihydropyridine analogues, and mibefradil using recombinant T- and L-type Ca²⁺ channels expressed separately in mammalian cells. All these Ca²⁺ channel antagonists blocked T-type Ca²⁺ channel currents (ICa(T)) with distinct blocking manners: ICa(T) was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC₅₀s of these Ca²⁺ channel antagonists to ICa(T) and L-type Ca²⁺ channel current (ICa(L)) were 1.2 µmol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 µmol/l for mibefradil, and 0.35 µmol/l and 1.8 nmol/l for efonidipine, respectively. Efonidipine, a dihydropyridine analogue, showed high affinity to T-type Ca²⁺ channel.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: